MedTrace Logo

Molecular Typing of Community-acquired Pneumonia Based on Multiple-omic Data Analysis

NCT03093220 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2017-03-28

No results posted yet for this study

Summary

Community-acquired pneumonia (CAP) is a heterogeneous disease causing great morbidity, mortality and health care burden globally. Typing methods for discriminating different clinical conditions of the same disease are essential to a better management of CAP. Traditional typing systems based separately on clinical manifestations (such as PSI and CURB-65), pathogens(bacterial types, virulence, drug resistance, etc) or host immune state (immunocompetent, immunocompromised or immunodeficiency). Thus, they are barely able to represent the real disease status nor to precisely predict the mortality.

As the development of multi-omic technologies, the relatedness of different phenotypes at a molecular level have revolutionized our ability to differentiate among patients. Our study is aimed at establishing a novel molecular typing method of CAP. Multi-omic (including genomics, transcriptomes, and metabolisms) data obtained from enrolled CAP patients and isolated pathogens would be integrated analyzed and interpreted. Tthe investigators believe that an appropriate molecular typing method would lead to revolutionary changes in current arrangements of CAP.

Conditions

Sponsors & Collaborators

  • CapitalBio Group Corporation

    collaborator UNKNOWN

  • Chinese Academy of Sciences

    collaborator OTHER_GOV

  • West China Hospital

    collaborator OTHER

  • Second Hospital of Jilin University

    collaborator OTHER

  • Shanghai Pulmonary Hospital, Shanghai, China

    collaborator OTHER

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Zhancheng Gao, Professor · Department of Respiratory Critical Care Medicine

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-31
Primary Completion
2018-03-31
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03093220 on ClinicalTrials.gov